Histopathological evolution of transient zolbetuximab-induced protein-losing gastropathy: insights from two surgical cases

Authors: Kaida, Sachiko; Mukaisho, Ken-Ichi; Fukuo, Asuka; Otake, Reiko; Takebayashi, Katsushi; Hosoi, Katsuma; Kageyama, Yusuke; Nakayama, Takahisa; Kushima, Ryoji; Tani, Masaji

Source journal: Virchows Archiv : an international journal of pathology (2026-11-21)

DOI: 10.1007/s00428-026-04785-8

Abstract

Zolbetuximab, a claudin 18.2 (CLDN18.2)-targeted antibody, can cause gastritis and hypoalbuminemia, but the histopathological basis and reversibility of this toxicity remain incompletely understood. We examined two patients who underwent gastrectomy after zolbetuximab-containing chemotherapy. Both developed diffuse erythematous hypertrophic gastropathy with severe hypoalbuminemia that subsequently improved despite continued therapy. Resected specimens showed extensive oxyntic gland loss, marked foveolar hyperplasia, MUC6-positive pseudopyloric m​etaplasia, preservation of the Ki67-positive proliferative isthmic compartment, and G-cell hyperplasia. Residual differentiated glandular cells strongly expressed CLDN18.2, whereas expression was weak in the proliferative compartment. In one patient, gastritis completely resolved in the remnant stomach one year after distal gastrectomy. These findings are consistent with preferential injury to CLDN18.2-expressing differentiated gastric epithelium with relative preservation of regenerative capacity, providing a histopathological framework for the transient nature of zolbetuximab-induced protein-losing gastropathy.

Read the full text

Related topics

Related open access articles

Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.